Following a two-year study, CooperVision’s SightGlass vision business reported that 85% of children wearing its Diffusion Optics Technology (DOT) lenses, designed to slow myopia, had <1.0D myopia progression.
The Cypress clinical study dispensed the lenses to 256 six-to-10-year-old children with between -0.75D and -4.50D myopia in a randomised trial across 14 clinical trial sites in the US and Canada. After two years, children who wore their DOT-enabled spectacles full-time, including not removing them for near-vision activities, had an average myopia progression of one-half diopter less than those wearing control spectacles. The study also showed that 41% of the children wearing the lenses showed no clinically meaningful progression in refractive error after two years, versus only 17% in the control group.
The news was presented during a launch event in the Netherlands, where Coopervision has begun to roll out the technology to eyecare professionals in collaboration with EssilorLuxottica.
